vs
Side-by-side financial comparison of DENNY'S Corp (DENN) and Vericel Corp (VCEL). Click either name above to swap in a different company.
DENNY'S Corp is the larger business by last-quarter revenue ($113.2M vs $92.9M, roughly 1.2× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 0.6%, a 24.5% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 1.3%). DENNY'S Corp produced more free cash flow last quarter ($16.0M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -0.9%).
Denny's is an American table service diner-style restaurant chain. It operates over 1,400 restaurants in the United States, Canada, México, Puerto Rico, and several other international locations.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
DENN vs VCEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $113.2M | $92.9M |
| Net Profit | $632.0K | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 9.2% | 24.1% |
| Net Margin | 0.6% | 25.0% |
| Revenue YoY | 1.3% | 23.3% |
| Net Profit YoY | -90.3% | 17.3% |
| EPS (diluted) | $0.01 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $92.9M | ||
| Q3 25 | $113.2M | $67.5M | ||
| Q2 25 | $117.7M | $63.2M | ||
| Q1 25 | $111.6M | $52.6M | ||
| Q4 24 | $114.7M | $75.4M | ||
| Q3 24 | $111.8M | $57.9M | ||
| Q2 24 | $115.9M | $52.7M | ||
| Q1 24 | $110.0M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $632.0K | $5.1M | ||
| Q2 25 | $2.5M | $-553.0K | ||
| Q1 25 | $326.0K | $-11.2M | ||
| Q4 24 | $6.8M | $19.8M | ||
| Q3 24 | $6.5M | $-901.0K | ||
| Q2 24 | $3.6M | $-4.7M | ||
| Q1 24 | $4.7M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | 9.2% | 5.1% | ||
| Q2 25 | 7.3% | -3.2% | ||
| Q1 25 | 4.7% | -24.3% | ||
| Q4 24 | 12.6% | 24.5% | ||
| Q3 24 | 10.5% | -4.3% | ||
| Q2 24 | 7.9% | -11.5% | ||
| Q1 24 | 9.1% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | 0.6% | 7.5% | ||
| Q2 25 | 2.1% | -0.9% | ||
| Q1 25 | 0.3% | -21.4% | ||
| Q4 24 | 5.9% | 26.3% | ||
| Q3 24 | 5.8% | -1.6% | ||
| Q2 24 | 3.1% | -8.9% | ||
| Q1 24 | 4.3% | -7.5% |
| Q4 25 | — | $0.46 | ||
| Q3 25 | $0.01 | $0.10 | ||
| Q2 25 | $0.05 | $-0.01 | ||
| Q1 25 | $0.01 | $-0.23 | ||
| Q4 24 | $0.13 | $0.40 | ||
| Q3 24 | $0.12 | $-0.02 | ||
| Q2 24 | $0.07 | $-0.10 | ||
| Q1 24 | $0.09 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-32.7M | $354.6M |
| Total Assets | $502.9M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | $1.1M | $112.9M | ||
| Q4 24 | $100.0K | $116.2M | ||
| Q3 24 | $2.9M | $101.7M | ||
| Q2 24 | $2.8M | $102.5M | ||
| Q1 24 | $2.8M | $110.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $270.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $354.6M | ||
| Q3 25 | $-32.7M | $321.9M | ||
| Q2 25 | $-34.6M | $306.8M | ||
| Q1 25 | $-36.4M | $295.5M | ||
| Q4 24 | $-34.0M | $292.0M | ||
| Q3 24 | $-54.5M | $257.5M | ||
| Q2 24 | $-53.2M | $243.0M | ||
| Q1 24 | $-55.7M | $233.9M |
| Q4 25 | — | $488.0M | ||
| Q3 25 | $502.9M | $453.3M | ||
| Q2 25 | $491.1M | $435.6M | ||
| Q1 25 | $488.1M | $424.6M | ||
| Q4 24 | $496.3M | $432.7M | ||
| Q3 24 | $461.6M | $390.4M | ||
| Q2 24 | $459.9M | $376.8M | ||
| Q1 24 | $460.4M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.0M | $15.0M |
| Free Cash FlowOCF − Capex | $16.0M | $12.8M |
| FCF MarginFCF / Revenue | 14.1% | 13.8% |
| Capex IntensityCapex / Revenue | 0.0% | 2.4% |
| Cash ConversionOCF / Net Profit | 25.28× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | $16.0M | $22.1M | ||
| Q2 25 | $9.4M | $8.2M | ||
| Q1 25 | $5.0M | $6.6M | ||
| Q4 24 | $8.5M | $22.2M | ||
| Q3 24 | $6.6M | $10.2M | ||
| Q2 24 | $14.2M | $18.5M | ||
| Q1 24 | $215.0K | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | $16.0M | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | 14.1% | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | 0.0% | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | 0.0% | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | 25.28× | 4.35× | ||
| Q2 25 | 3.79× | — | ||
| Q1 25 | 15.38× | — | ||
| Q4 24 | 1.26× | 1.12× | ||
| Q3 24 | 1.01× | — | ||
| Q2 24 | 3.97× | — | ||
| Q1 24 | 0.05× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DENN
| Franchisor Owned Outlet | $57.4M | 51% |
| Royalty | $27.7M | 25% |
| Advertising | $18.6M | 16% |
| Occupancy | $7.7M | 7% |
| Initial And Other Fees | $1.7M | 1% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
